Scarica l'app Stockscreener
34.56
1.26%
0.41
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché IMVT Giù?
Forum
Previsione
Precedente Chiudi:
$34.15
Aprire:
$34.95
Volume 24 ore:
389.27K
Relative Volume:
0.23
Capitalizzazione di mercato:
$7.10B
Reddito:
-
Utile/perdita netta:
$-464.20M
Rapporto P/E:
-12.88
EPS:
-2.6823
Flusso di cassa netto:
$-423.09M
1 W Prestazione:
+31.53%
1M Prestazione:
+20.99%
6M Prestazione:
+45.91%
1 anno Prestazione:
+139.14%
Intervallo 1D:
$33.62
$35.46
Intervallo di 1 settimana:
$30.10
$36.28
Portata 52W:
$13.79
$36.28
Immunovant Inc Stock (IMVT) Company Profile
Nome
Immunovant Inc
Settore
Industria
Telefono
917-410-3120
Indirizzo
1000 PARK FORTY PLAZA, DURHAM, NY
Compare IMVT vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IMVT
Immunovant Inc
|
34.59 | 7.01B | 0 | -464.20M | -423.09M | -2.6823 |
VRTX
Vertex Pharmaceuticals Inc
|
437.23 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
639.77 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.50 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.70 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.71 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Immunovant Inc Stock (IMVT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-20 | Iniziato | Bernstein | Mkt Perform |
| 2026-01-06 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2025-10-14 | Iniziato | Truist | Hold |
| 2025-07-10 | Ripresa | Goldman | Neutral |
| 2025-03-03 | Iniziato | Jefferies | Hold |
| 2025-01-03 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-10-09 | Reiterato | Oppenheimer | Outperform |
| 2024-03-28 | Iniziato | Oppenheimer | Outperform |
| 2024-03-13 | Iniziato | Goldman | Buy |
| 2024-02-20 | Iniziato | JP Morgan | Overweight |
| 2024-02-15 | Iniziato | Wolfe Research | Outperform |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-10-13 | Aggiornamento | UBS | Neutral → Buy |
| 2023-09-26 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-05-01 | Iniziato | BofA Securities | Buy |
| 2023-04-25 | Iniziato | Citigroup | Buy |
| 2023-03-31 | Iniziato | Piper Sandler | Overweight |
| 2023-03-30 | Iniziato | Stifel | Buy |
| 2023-02-15 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-02-13 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-01-03 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-09-26 | Downgrade | UBS | Buy → Neutral |
| 2021-12-08 | Iniziato | Wells Fargo | Equal Weight |
| 2021-08-03 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2021-08-02 | Downgrade | Credit Suisse | Neutral → Underperform |
| 2021-06-01 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-06-01 | Downgrade | Stifel | Buy → Hold |
| 2020-10-28 | Iniziato | UBS | Buy |
| 2020-10-12 | Iniziato | Guggenheim | Buy |
| 2020-10-08 | Iniziato | Stifel | Buy |
| 2020-10-02 | Iniziato | Credit Suisse | Outperform |
| 2020-08-26 | Reiterato | H.C. Wainwright | Buy |
| 2020-08-25 | Iniziato | Raymond James | Outperform |
| 2020-07-29 | Iniziato | H.C. Wainwright | Buy |
| 2020-02-24 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Immunovant Inc Borsa (IMVT) Ultime notizie
CrowdStrike To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Nvidia, Astera Labs, Micron, Intel, United, Hasbro, Toll, Immunovant, Analog Devices, and More Movers - Barron's
IMVT rockets 35% despite wider loss as arthritis drug shines in study - MSN
Stifel Maintains Immunovant(IMVT.US) With Buy Rating, Maintains Target Price $49 - Moomoo
Immunovant: Upgraded To 'Buy' Because Of IMVT-1402's Broad Potential (NASDAQ:IMVT) - Seeking Alpha
(IMVT) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
IMVT's Q4 loss wider than expected, stock up 35% on strong study data - MSN
Immunovant (IMVT) Is Up 24.2% After Axing Batoclimab To Back IMVT-1402 Autoimmune PivotHas The Bull Case Changed? - simplywall.st
symbol__ Stock Quote Price and Forecast - CNN
Immunovant COO Gloria Melanie sells $101,072 in company stock - Investing.com
Immunovant COO Gloria Melanie sells $101,072 in company stock By Investing.com - Investing.com South Africa
[Form 4] Immunovant, Inc. Insider Trading Activity - Stock Titan
Wells Fargo Sticks to Its Buy Rating for Immunovant (IMVT) - The Globe and Mail
These Analysts Increase Their Forecasts On Immunovant After Q4 Results - Sahm
BofA Securities Maintains Immunovant(IMVT.US) With Buy Rating, Raises Target Price to $43 - Moomoo
Immunovant’s Talent Crunch: How Human Capital Risks Could Derail IMVT-1402 Development Across Six Indications - TipRanks
Immunovant (IMVT) Is Up 17.9% After Refocusing On IMVT-1402 Amid Wider LossesHas The Bull Case Changed? - Yahoo Finance
Immunovant director Atul Pande sells $192,000 in shares By Investing.com - Investing.com Nigeria
IMVT Maintains Buy Rating by B of A Securities -- Price Target R - GuruFocus
IMVT Maintains by HC Wainwright & Co. -- Price Target Raised to $40 - GuruFocus
Immunovant (IMVT) Stock Shot up after a Poor Quarterly Showing - FXLeaders
Roivant: Immunovant's Rheumatoid Arthritis Win Validates The Buy (NASDAQ:ROIV) - Seeking Alpha
LifeSci Capital Maintains Immunovant(IMVT.US) With Buy Rating, Raises Target Price to $45 - Moomoo
IMVT's Q4 Loss Wider Than Expected, Stock Up 35% on Strong Study Data - The Globe and Mail
BofA raises Immunovant stock price target on higher peak sales outlook - Investing.com
A Quick Look at Today's Ratings for Immunovant(IMVT.US), With a Forecast Between $40 to $45 - Moomoo
Immunovant director Atul Pande sells $192,000 in shares - Investing.com India
Immunovant (IMVT) Hits 5-Year High on Stellar Arthritis Treatment Trial - Insider Monkey
Immunovant (IMVT) director exercises options, sells 6,000 shares under 10b5-1 plan - Stock Titan
Immunovant, Inc. Stock 12‑Month Price Target Raised to $43.67, Implies 66% Upside - TradingView
Immunovant Stock Surges 35% After Arthritis Drug Data: Why Wall Street Is Repricing IMVT - TechStock²
Roivant/Immunovant Find Success In Tough-To-Treat RA, Where J&J Failed - Citeline News & Insights
IMVT Stock Jumps As Traders Track Insider Ownership Filing - timothysykes.com
Immunovant rises on IMVT-1402 data in difficult-to-treat RA - BioWorld News
2 Biotech Stocks Are Surging Today Thanks to This Arthritis Drug - Barron's
[144] Immunovant, Inc. SEC Filing - Stock Titan
Immunovant Shares Just Surged 35% – Here’s Why - AskTraders
Immunovant stock hits 52-week high at 30.27 USD By Investing.com - Investing.com Australia
Immunovant, Inc. Stock 12‑Month Price Target Raised to $43.08, Implies 64% Upside - TradingView
Immunovant (IMVT) Stock Soars Over 20% Following Breakthrough Rheumatoid Arthritis Data - MEXC
Stifel reiterates Immunovant stock rating on trial results - Investing.com
Immunovant Stock Surges Despite Disappointing Earnings Miss - Benzinga
Stifel reiterates Immunovant stock rating on trial results By Investing.com - Investing.com Australia
Immunovant, Inc. Stock 12‑Month Price Target Raised to $42.55, Implies 62% Upside - TradingView
Crude Oil Down 5%; Lowe's Posts Upbeat EarningsImmunovant (NASDAQ:IMVT), Lowe's Companies (NYSE:LOW) - Benzinga
Immunovant (IMVT) Stock Surges 22% on Positive Rheumatoid Arthritis Trial Data - MEXC
These Stocks Are Today's Movers: Nvidia, Micron, Intel, United, Hasbro, Toll, Immunovant, Analog Devices, and More -- Barrons.com - Moomoo
Immunovant Inc Azioni (IMVT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Immunovant Inc Azioni (IMVT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Pande Atul | Director |
May 20 '26 |
Option Exercise |
8.43 |
6,000 |
50,580 |
122,731 |
| Pande Atul | Director |
May 20 '26 |
Sale |
32.00 |
6,000 |
192,000 |
116,731 |
2.25%
0.46%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):